Events

Join the Programs in Occupational Therapy for an information session about our entry level Masters program. Attendees at in person sessions must submit proof of vaccination and sign an attestation before the session. RSVP at the link below and more information will be provided before the date of the session: https://cumc.co1.qualtrics.com/jfe/form/SV_5d03hIeNBalADk2

In this session, experts from Columbia University Herbert Irving Comprehensive Cancer Center will share updates in the treatment of acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL), including newly approved therapies and treatment options such as cell therapies. In addition, issues in allogeneic transplant for AML will be discussed, including strategies like micro-transplant and new approaches for GVHD treatment. New directions in treatment in terms of ongoing clinical trials in AML and ALL will also be shared. Target audience – medical oncologists, trainees, other allied health professionals AGENDA Updates on the Treatment of AML Joseph G. Jurcic, MD, Professor of Medicine at CUMC; Director, Hematologic Malignancies Section, Columbia University Vagelos College of Physicians and Surgeons Issues in Allogeneic Transplant for AML Amer Assal, MD, Assistant Professor of Medicine at CUMC, Columbia University Vagelos College of Physicians and Surgeons New Approaches for ALL Andrew Lipsky, MD, Assistant Professor of Medicine at CUMC, Columbia University Vagelos College of Physicians and Surgeons Cell Therapies for ALL + AML Ran Reshef, MD, Associate Professor of Medicine at CUMC, Columbia University Vagelos College of Physicians and Surgeons Upon conclusion of this activity, participants will be better able to: Describe promising new therapies for AML/ALL Discuss principles of cell therapies and transplant and when the therapies can be utilized Describe a patient journey from diagnosis to end of treatment This activity has been approved for AMA PRA Category 1 CreditsTM

This two-day course will cover virtually all aspects of neonatal respiratory care, including kinder, gentler mechanical ventilation, NAVA, high frequency ventilation, non-invasive modes of respiratory support, oxygen targeting, one-lung ventilation, surfactant therapy, inhaled nitric oxide therapy, and the use of laryngeal mask airway. Participants will become familiar with the application and pitfalls of bubble nasal prong CPAP therapy and ventilatory strategies in infants with respiratory distress. We will also address strategies for CPAP success from nursing perspective, clinical care of patients with RDS, persistent pulmonary hypertension in term and preterm infants, pulmonary hypertension in infants with chronic lung disease, and fetal surgery. In addition, innovations in monitoring during neonatal intensive care, golden hour management, screening for congenital heart disease, comfort care, point of care sonography, and ‘Pearls in Neonatology’ will be discussed. The main learning objectives of the conference are that at the conclusion of this conference, participants will be able to recognize the rationale for using bubble nasal CPAP, familiarize with practical aspects of effective bubble CPAP use, identify strategies for replicating and evaluating success with bubble nasal CPAP and other respiratory care practices at their own institutions. This two-day course will cover virtually all aspects of neonatal respiratory care, including kinder, gentler mechanical ventilation, NAVA, high frequency ventilation, non-invasive modes of respiratory support, oxygen targeting, one-lung ventilation, surfactant therapy, inhaled nitric oxide therapy, and the use of laryngeal mask airway. Participants will become familiar with the application and pitfalls of bubble nasal prong CPAP therapy and ventilatory strategies in infants with respiratory distress. We will also address strategies for CPAP success from nursing perspective, clinical care of patients with RDS, persistent pulmonary hypertension in term and preterm infants, pulmonary hypertension in infants with chronic lung disease, and fetal surgery. In addition, innovations in monitoring during neonatal intensive care, golden hour management, screening for congenital heart disease, comfort care, point of care sonography, and ‘Pearls in Neonatology’ will be discussed.  CLICK HERE TO VIEW THE AGENDA